STOP T1D

04/28/2026

People managing T1D and who are pregnant may now use AID system to manage their insulin. Research studies showed this AID system to be safe and effective during pregnancy.

"The mean percentage of time spent in the pregnancy-specific glucose range (63-140 mg/dL) from 16 to 34 weeks’ gestation was 65.4% in the AID group vs 50.3% in the standard care group, a statistically significant difference."

Automated Insulin Delivery Cleared for Pregnant T1D Patients https://www.medscape.com/viewarticle/automated-insulin-delivery-system-cleared-pregnant-t1d-2026a1000ddi

The FDA has cleared Tandem’s Control-IQ technology as the first ever AID specifically for use in pregnancies complicated by type 1 diabetes.

04/21/2026

in Australia think they may have created a dual wearable device to detect blood glucose levels and deliver insulin as needed. More work on perfecting the device and studying its results are required, but early trials look promising.

Combining Insulin Pump, CGM Into One Device Appears Feasible https://www.medscape.com/viewarticle/combining-insulin-pump-and-cgm-one-device-appears-feasible-2026a1000ci3

Early proof-of-concept study showed that a patch pump with integrated glucose sensing at the site of insulin delivery can function in people with type 1 diabetes.

04/17/2026

For people managing their glucose levels, monk fruit may be a reasonable alternative to other sweeteners that may spike blood glucose or insulin levels.

From the article: "Monk fruit appears to be metabolically neutral with no significant effect on glucose or insulin. It’s generally well tolerated, especially compared to sugar alcohols. It’s not a proven gut health intervention despite marketing claims. For patients looking to reduce added sugar, monk fruit can be a reasonable alternative, particularly when used in small amounts and in simpler formulations."

Monk Fruit and Its Impact on the Gut https://www.medscape.com/viewarticle/monk-fruit-and-its-impact-gut-2026a1000arh

Dr Alicia Muratore discusses monk fruit, including where it comes from, why it’s used so widely, and what the evidence actually tells us about its effect on the gut and metabolic health.

04/15/2026

⚕️ ASK THE EXPERTS - Health Care Professionals are invited to join researchers from Barbara Davis Center for Diabetes on Wednesday, April 22, 2026 | NOON (MST) / 2PM (EST)

This is an interactive 1-hr Zoom call to discuss early questions and cases.
Hosted by the Ask the Experts Team

Office hours are scheduled, drop-in sessions for health care professionals ( ) to ask practical clinical questions, clarify concepts, and get real-time guidance from experts and colleagues in an interactive online forum format.

Register and attend online:

Registration Form for our monthly "Office Hours" Zoom call for HCPs — to discuss early T1D questions and cases.

04/14/2026

Screen TO Prevent: The STOP T1D Mission — Join us to enact widespread T1D screening.

Your experience with screening is important for us to better understand the barriers and limitations faced by people who test positive for autoantibodies.

People managing diabetes* are encouraged to join the STOP T1D Registry.

The purpose of the STOP T1D Registry is to improve the quality of screening and monitoring for type 1 diabetes (T1D) in the United States. We are doing this by collecting information from people who have been screened and tested positive for pre-symptomatic T1D (autoantibodies), regardless of whether they have been later diagnosed with symptomatic Stage 3 T1D.

Learn more and sign up: https://www.stopt1dprogram.org/registry-overview

*For patients under 18 years, we ask that their parents/legal guardians provide the information on their behalf.

04/10/2026

Recent * on 's role in developing "Alzheimer’s disease and related dementias (AD/ADRD)" may be related to having "a history of DKA was associated with increased NfL concentrations. While the association between NfL and DKA has not been directly examined, increased NfL has been associated with impaired glycemic control (i.e., higher HbA1c), suggesting that inflammatory and metabolic changes during acute and prolonged glycemic events may contribute to neuronal injury. Further research is needed to clarify the long-term impact of on neurodegeneration risk."

Read: Plasma biomarkers of neurodegeneration and their associations with type 1 diabetes characteristics and glycemia https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(26)00175-0/fulltext

*see article for citations

Type 1 diabetes (T1D) is a chronic autoimmune disorder affecting over eight million adults worldwide–with incidence increasing–and is associated with substantial microvascular and macrovascular complications (i.e., nephropathy, neuropathy, retinopathy, cardiovascular disease) [1–5]. Improved l...

04/09/2026

New in from the UK: "Hypo- and hyperglycaemia following pancreas transplantation for people with type 1 diabetes"

"Recipients with post-transplantation hypoglycaemia were more likely to be women and of low body weight, which may be due to disordered eating with restricted calorie or carbohydrate intake. Recipients with post-transplantation hyperglycaemia had features of insulin resistance and type 2 diabetes with increased weight and men predominance. Glycaemic disturbance was not associated with graft failure, suggesting it relates to insulin–glucose mismatch rather than rejection. Further follow-up is required to identify the long-term sequelae of glycaemic disturbance after pancreas transplants and if relevant dietary counselling has the potential to attenuate these disturbances."

Diabetic Medicine | Diabetes UK Journal | Wiley Online Library https://onlinelibrary.wiley.com/doi/10.1111/dme.70307

04/08/2026

Health Care Providers: This American Diabetes Association 2026 Abridged Standards of Care publication is for you!

2026 Abridged Standards of Care | American Diabetes Association https://diabetesjournals.org/collection/18339/2026-Abridged-Standards-of-Care

T2D

This collection provides an abridged version of the American Diabetes Association’s (ADA’s) Standards of Care in Diabetes—2026 designed especially for primary care professionals. Developed by the ADA’s Primary Care Advisory Group*, this new resource contains the evidence-based clinical pract...

04/08/2026

What is Type 1 Diabetes?

Type 1 diabetes (T1D) is an autoimmune disease — that means your immune system is attacking your own body.

(T1D) is a condition that can affect anyone, no matter their age or family history. By getting screened for T1D-related autoantibodies, you can find out if you are more likely to develop T1D.

T1D screenings are available at no cost for children and adults through the ASKhealth.org screening program.

Being aware that you are at high risk for T1D enables you to recognize symptoms early, participate in prevention research trials, and explore therapy options to postpone the onset of clinical T1D.

Learn more: STOPT1Dprogram.org

source: https://medschool.cuanschutz.edu/barbara-davis-center-for-diabetes/patient-care/early-t1d-clinic

04/06/2026

Catch up on the drugs and therapies in development for and the phases these T1D trials are currently in.

"Breakthrough T1D is focused on developing drugs, or disease-modifying therapies (DMTs), that change the course of T1D for everyone affected by it—and those yet to be. That means slowing or halting the progression of the disease, preventing it from ever occurring, and reversing it entirely through immune therapies and beta cell therapies."

Disease-Modifying Therapies and DIAGNODE-3 Update - Breakthrough T1D https://www.breakthrought1d.org/news-and-updates/disease-modifying-therapies-and-diagnode-3-update/

Breakthrough T1D is focused on developing drugs, or disease-modifying therapies (DMTs), that change the course of T1D for everyone affected by it—and those yet to be. That means slowing or halting the progression of the disease, preventing it from ever occurring, and reversing it entirely throu...

04/02/2026

Gene Therapy to Be Studied for Treating Type 1 Diabetes > https://www.medscape.com/viewarticle/gene-therapy-be-studied-treating-type-1-diabetes-2026a10009xh

"In Kriya’s [KRIYA-839 ] approach, the two genes within the AAV are delivered into the thigh muscle, where the cells aren’t actively dividing. The muscle then secretes insulin, which activates glucose transporter type 4 to bring glucose into the cells, its normal action. For its part, GCK is activated at higher glucose levels to move glucose out of the bloodstream, while remaining inactive when blood glucose levels are low. “So it has a glucose sensing kind of quality to it." - Jeremy Pettus, MD, Endocrinologist and Associate Professor of Medicine at the University of California, San Diego

A phase 1/2 trial of a novel viral vector gene therapy in adults with type 1 diabetes is scheduled to begin this year.

04/01/2026

New in : Tirzepatide Boosts Metabolic Health in Partial Lipodystrophy https://www.medscape.com/viewarticle/tirzepatide-boosts-metabolic-health-partial-lipodystrophy-2026a10009fu

"In patients with partial lipodystrophy (PLD), treatment with — a dual glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonist — was associated with significant reductions in body weight; A1c, serum triglyceride, and alanine aminotransferase levels; and daily insulin requirements."

Tirzepatide significantly improves metabolic health and reduces insulin dependence in patients with partial lipodystrophy.